Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Sep 6;125(5):286-8.
doi: 10.1590/s1516-31802007000500007.

Primary testicular non-Hodgkin's lymphoma--a review article

Komal Bhatia  1 , Ashok Kumar Vaid, Sachin Gupta, Dinesh Chandra Doval, Vineet Talwar
Affiliations
Review

Primary testicular non-Hodgkin's lymphoma--a review article

Komal Bhatia et al. Sao Paulo Med J. .

Abstract
in English, Portuguese

Primary testicular non-Hodgkin's lymphoma was first described as a clinical entity in 1866. It is a rare disease and accounts for 1% of all non-Hodgkin's lymphoma, 2% of all extranodal lymphomas and 5% of all testicular neoplasms. It is the most common testicular tumor in males between sixty and eighty years of age. Testicular non-Hodgkin's lymphoma is unique in its high incidence of bilateral involvement (8-38%), and it is also the most common bilateral testicular tumor. Testicular non-Hodgkin's lymphoma has a predilection for spreading to non-contiguous extranodal sites, especially the central nervous system. Advanced-stage disease is usually managed with doxorubicin-based chemotherapy. For early-stage disease, opinion is divided regarding systemic chemotherapy following orchidectomy. The high incidence of spreading, especially to the central nervous system, leads to advocacy of the use of central nervous system prophylaxis with intrathecal chemotherapy. Prospective multicenter trials incorporating a large number of patients may lead to better guidelines for optimal management of this subtype of non-Hodgkin's lymphoma.

O linfoma primário do testículo (LPT) foi descrito como uma entidade clínica pela primeira vez em 1866. É uma doença rara e corresponde a 1% de todos os linfomas não-Hodgkin, 2% de todos os linfomas extranodais e 5% de todos as neoplasias testiculares. É o tumor testicular mais comum em homens entre 60 e 80 anos de idade. LPT é único em sua elevada incidência de envolvimento bilateral (8-38%), sendo o tumor testicular bilateral mais comum. Tem uma predileção por disseminação para regiões extranodais não-contíguas, especialmente para o sistema nervoso central (SNC). Estágios avançados da doença são usualmente tratados com quimioterapia à base de doxorubicina. Para os estágios mais precoces, as opiniões são divergentes quanto à quimioterapia associada à orquiectomia. A alta prevalência de disseminação, especialmente para o SNC, sugere o uso de quimioterapia intratecal como profilaxia. Estudos prospectivos multicêntricos incluindo um grande número de pacientes poderiam resolver a questão com relação ao manejo deste subtipo de linfoma não-Hodgkin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None

References

    1. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999;26(3):259–269. - PubMed
    1. Eskey CJ, Whitman GJ, Chew FS. Malignant lymphoma of the testis. AJR Am J Roentgenol. 1997;169(3):822–822. - PubMed
    1. Ballen KK, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement. N Engl J Med. 2004;350(20):2081–2087. - PubMed
    1. Buskirk SJ, Evans RG, Banks PM, O'Connell MJ, Earle JD. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys. 1982;8(10):1699–1703. - PubMed
    1. Lobo FD, Bansal R, Naik R, Pai MR, Dinesh D. Primary testicular lymphoma. J Indian Med Assoc. 1998;96(6):193–194. - PubMed

MeSH terms